Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. on November 3, 2011. The filing serves to announce the company's financial results for the quarter ended September 30, 2011. The report incorporates a press release (Exhibit 99.1) by reference but explicitly states that the press release is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934.
Key Financial Metrics
The provided filing text does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide details on material changes versus the prior comparable period. It only confirms the issuance of a press release announcing the results for the quarter ended September 30, 2011.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, contingencies, or unusual items. The document functions solely as a notification of the press release's existence.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release), as they are absent from the 8-K body text.
- Confirm the company's current operational status and cash runway, given the filing only announces results without detailing the magnitude of performance.
- Note that the press release is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.